Chemokines as Cancer Vaccine Adjuvants

We are witnessing a new era of immune-mediated cancer therapies and vaccine development. As the field of cancer vaccines advances into clinical trials, overcoming low immunogenicity is a limiting step in achieving full success of this therapeutic approach. Recent discoveries in the many biological r...

Full description

Saved in:
Bibliographic Details
Published inVaccines (Basel) Vol. 1; no. 4; pp. 444 - 462
Main Authors Bobanga, Iuliana D, Petrosiute, Agne, Huang, Alex Y
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 01.12.2013
MDPI
Subjects
adjuvant
Cancer
cancer vaccine
Chemokines
dendritic cell
Immunogenicity
Immunology
Immunotherapy
Review
Vaccines
chemokines
adjuvant
cancer vaccine
dendritic cell
immunotherapy
Online AccessGet full text

Cover

More Information
Summary:We are witnessing a new era of immune-mediated cancer therapies and vaccine development. As the field of cancer vaccines advances into clinical trials, overcoming low immunogenicity is a limiting step in achieving full success of this therapeutic approach. Recent discoveries in the many biological roles of chemokines in tumor immunology allow their exploitation in enhancing recruitment of antigen presenting cells (APCs) and effector cells to appropriate anatomical sites. This knowledge, combined with advances in gene therapy and virology, allows researchers to employ chemokines as potential vaccine adjuvants. This review will focus on recent murine and human studies that use chemokines as therapeutic anti-cancer vaccine adjuvants.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2076-393X
2076-393X
DOI:10.3390/vaccines1040444